• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Mogamulizumab for the treatment of T-cell lymphoma
【24h】

Mogamulizumab for the treatment of T-cell lymphoma

机译：用于治疗T细胞淋巴瘤的Mogamulizumab

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: T-cell lymphoma is a relatively rare hematologic malignancy that accounts for 10-20% of non-Hodgkin lymphomas. Treatment strategies for T-cell lymphomas are different from that for B-cell lymphomas and have poor prognoses. Among various subtypes of T-cell lymphomas, adult T-cell leukemia-lymphoma (ATL) has the worst prognosis. To achieve further improvement in the treatment outcome of T-cell lymphomas, several novel agents such as brentuximab vedotin, lenalidomide, romidepsin, and pralatrexate are actively being studied. Mogamulizumab, an anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, is one of the promising agents for CCR4-positive T-cell lymphomas, especially for ATL.Areas covered: First, basic information about the current treatment strategy of T-cell lymphomas including ATL is described. Then, the authors discuss the current clinical development of mogamulizumab and its clinical implications for T-cell lymphomas.Expert opinion: Mogamulizumab has potent clinical efficacy against CCR4-positive T-cell lymphomas, especially against ATL. Among various toxicities associated with mogamulizumab, skin eruptions are the most significant. Although there are several effective competitors, mogamulizumab has a unique mechanism and is expected to be a key agent for treating CCR4-positive T-cell lymphomas, especially ATL.
机译：简介：T细胞淋巴瘤是一种相对罕见的血液学恶性肿瘤，占非霍奇金淋巴瘤的10-20％。 T细胞淋巴瘤的治疗策略与B细胞淋巴瘤的含量不同，并具有较差的预测。在T细胞淋巴瘤的各种亚型中，成人T细胞白血病 - 淋巴瘤（ATL）预后最糟糕。为了进一步改善T细胞淋巴瘤的治疗结果，正在积极研究几种新的药物，如短妥昔单抗，葡萄球菌，树脂，Romidepsin和雷大甲酸甲醛。 Mogamulizumab，一种抗CC趋化因子受体4（CCR4）单克隆抗体，是CCR4阳性T细胞淋巴瘤的有希望的药剂之一，特别是对于ATL.AREAS涵盖：第一，关于T细胞目前治疗策略的基本信息描述包括ATL的淋巴瘤。然后，作者讨论了Mogamulizumab的当前临床开发及其对T细胞淋巴瘤的临床意义.Pert意见：Mogamulizumab对CCR4阳性T细胞淋巴瘤具有有效的临床疗效，尤其是抗ATL。在与乳头素酸相关的各种毒性中，皮肤爆发是最重要的。虽然有几个有效的竞争对手，但莫伐木制具有独特的机制，预计将成为治疗CCR4阳性T细胞淋巴瘤，特别是ATL的关键剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号